Mugwort

Mugwort (Artemisia vulgaris L.): A Comprehensive Reference

1. Identity and Botanical Characterization

Taxonomic and Nomenclatural Identity

Artemisia vulgaris L. (common mugwort) is a species with great importance in the history of medicine and was called the "mother of herbs" in the Middle Ages. It belongs to the family Compositae (Asteraceae). In English it is also known as mugwort or wormwood; in Hindi as Nagadouna; and in Tamil as Mashibattiri or Machipatri. Additional vernacular names documented in the literature include chrysanthemum weed, felon weed, common artemisia, French tobacco, wild wormwood, and mugweed.

"Mugwort" is a common name for several species of aromatic flowering plants in the genus Artemisia. In Europe, mugwort most often refers to Artemisia vulgaris, or common mugwort. In East Asia, the species Artemisia argyi is often called "Chinese mugwort" in the context of traditional Chinese medicine; while Artemisia princeps is known in Korea as ssuk (쑥) and in Japan as yomogi (ヨモギ). This article focuses primarily on Artemisia vulgaris L., which is the subject of the preponderance of phytochemical and clinical research.

It is a common herbaceous plant that exhibits high morphological and phytochemical variability depending on the location where it occurs; this species is well known almost all over the world. Its native habitats include temperate Asia, Europe, Northern Africa, and Alaska.

Pharmacopoeial Status

The herb—Artemisiae vulgaris herba—is used as a raw material due to the presence of essential oil, flavonoids, and sesquiterpenoid lactones and their associated biological activities. The European Pharmacopoeia has listed this species as a potential homeopathic raw material.

Common Forms and Preparations

Mugwort is available in and traditionally prepared as several distinct forms:

• Infusions/herbal teas: These are prepared by pouring boiling water over one teaspoon (about 1.2 g) of dried herb and brewing the mixture covered for about 5 minutes.
• Tinctures: Another form of mugwort medication used in allopathy is tinctures, which are sold all over Europe.
• Moxa (moxibustion cones and sticks): In TCM, A. vulgaris is most often used in thermopuncture in the form of cotton buds impregnated with plant extract, or as cigarettes filled with dried leaves and used to cauterize the skin.
• Culinary spice: The species is highly valued as a spice because of the aroma and bitter taste of the herb and the sweet and spicy taste of the roots. The leaves and buds collected just before flowering are used as a bitter additive for seasoning rice dishes and tea in Asia. The species is also used as an additive to meat, poultry, fish, and salads, in the production of vodkas and herbal wines, and in the preparation of sweet and savory cakes (especially in Japan). Before the introduction of hops, A. vulgaris had been used to flavor beer.
• Powdered herb and capsules: Dried plant material is also processed into powdered form for oral use.
• Essential oil: One of the significant therapeutic plant species in the genus Artemisia is A. vulgaris, which is typically recognized for its volatile oil.

2. Traditional and Historical Use

Ancient and Classical Antiquity

Due to its widespread occurrence, A. vulgaris was well known in ancient Egypt, Greece, and Rome. According to ancient belief, its name is derived from the name of the Greek goddess Artemis, who is the patron of pregnant women and newly delivered mothers. Because of its beneficial effects on menstruation- and pregnancy-related ailments, it became closely associated with women's medicine in the ancient world.

Medieval European Medicine

Artemisia vulgaris, a species which played a significant role in the history of European medicine, was referred to in the Middle Ages as the "mother of herbs," and used inter alia in treating gynecological and urological ailments and gastrointestinal disorders. The Anglo-Saxon Nine Herbs Charm mentions mucgwyrt by name, attesting to its importance in early medieval English herbal tradition. Before the introduction of hops in the beer-making process, A. vulgaris was commonly used in England as a flavoring agent. Dried mugwort flowers were added to malt liquor, and this was added to the beer. Mugwort has been used as one of the traditional flavoring and bittering agents of gruit ales, a type of unhopped, fermented grain beverage.

Traditional Chinese Medicine (TCM)

This species has been used in traditional Chinese, Hindu, and European medicine to regulate the functioning of the gastrointestinal system and treat various gynecological diseases. In TCM, the most prominent use of dried mugwort is moxibustion. Moxibustion is a traditional Chinese technique involving the burning of dried mugwort ("moxa") near a specific acupuncture point on the little toe, and has been used in China for over two thousand years to encourage a breech baby to turn to a head-down position.

South and Southeast Asian Traditions

Traditionally in Southeast Asia, A. vulgaris is used to treat menstrual conditions such as amenorrhea, dysmenorrhea, and oligomenorrhea, pregnancy disorders, and severe pain during labor and leucorrhea. Ethnomedicinally, it is also used in traditional treatments to treat depression, epilepsy, irritability, insomnia, and stress. In the Philippines, this plant is called Herbaka and is used to alleviate hypertension.

Food and Culinary Traditions

In Vietnam as well as in Germany, mugwort is used in cooking as an aromatic herb. In China, the crunchy stalks of young shoots of A. vulgaris are a seasonal vegetable often used in stir fries. It is utilized as a culinary herb in western countries and is often used to flavor rice dishes and tea in Asia.

Dermatological and External Uses

Customarily, decoctions of Artemisia vulgaris and Artemisia absinthium (Compositae) have been used to treat ulcerative sores, eczema, herpes, and purulent scabies.

3. Key Constituents and Active Compounds

Overview of Phytochemical Profile

The different applications of this plant species have been possible due to its rich chemical composition, which especially includes essential oils, flavonoids, sesquiterpene lactones, phenolic acids, coumarins, and other groups of metabolites. Phytochemical studies have proved the rich composition of the aerial parts of this plant, which consists of sesquiterpenoid lactones, flavonoids, and coumarins, and an essential oil made of qualitatively variable components.

Essential Oil

The presence of essential oil is an interesting characteristic of A. vulgaris. A major part of the oil extracted from the aerial parts is constituted by monoterpenoids (72%) and sesquiterpenoids (26%). The specific composition of the essential oil varies markedly by geographic origin. The essential oil of A. vulgaris is present up to 0.3% and comprises 1,8-cineole, sabinene, β-thujone, and caryophyllene oxide as the main constituents. One study analyzing essential oil from Nepal found that sabinene (11.29%), β-thujone (19.19%), chrysanthenone (4.48%), camphor (11.89%), borneol (4.44%), and germacrene D (8.42%) were the major compounds. A study on Brazilian-cultivated A. vulgaris reported that the essential oil was dominated by oxygenated sesquiterpenes (44.4%), sesquiterpene hydrocarbons (33.3%), and oxygenated monoterpenes (16.6%), with caryophyllene (37.45%), germacrene D (16.17%), and humulene (13.66%) as the major components. These population-level differences in chemical composition are consistent with the plant's high morphological and phytochemical variability depending on the location where it occurs.

Sesquiterpene Lactones

A characteristic feature of this species is the presence of sesquiterpenoid lactones, including psilostachyin, psilostachyin C, and vulgarin, and also artemisinin has been confirmed. These sesquiterpene lactones are largely responsible for the therapeutical potential of the Artemisia genus. The Frontiers in Chemistry journal has highlighted research into these constituents as traditional medicinal uses for relieving pain and treating gynecological symptoms in folk medicine; the chemical constituents contain mainly polysaccharides, flavonoids, terpenoids, and sterols, showing anti-tumor, anti-inflammatory, hepatoprotective, antioxidant, immunomodulatory, anti-allergic, and anti-bacterial activities.

Flavonoids

Flavonoids in A. vulgaris include derivatives of kaempferol and quercetin. HPLC analysis of the methanol extract of A. vulgaris reveals the presence of luteolin and morin. The presence of flavonoids eriodictyol and apigenin in A. vulgaris, with their weak estrogenic activity, may account for its folkloric use to treat menstrual disorders, as an emmenagogue and uterine relaxant.

Coumarins and Phenolic Acids

Additional phytochemicals confirmed in A. vulgaris include coumarins (coumarin, esculin, scopoletin, and umbelliferone) and phenolic acids (caffeic and chlorogenic acids), as well as sterols, carotenoids, and polyacetylenes.

Thujone

Thujone is a monoterpene ketone present in the essential oil of A. vulgaris and is among its most pharmacologically and toxicologically significant constituents. The EFSA notes that the ingredients in the essential oil of A. vulgaris herb, such as α-thujone, β-thujone, camphor, and 1,8-cineole, have potentially adverse effects on human health when taken with food or dietary supplements; however, it emphasizes that most research has concerned only a more concentrated oil, and not a less concentrated extract.

4. Established and Proposed Mechanisms of Action

Antispasmodic / Smooth Muscle Effects

The flavonoids eriodictyol and apigenin in A. vulgaris possess weak estrogenic activity, which may account for its folkloric use to treat menstrual disorders, as an emmenagogue and uterine relaxant. Furthermore, relaxing activities in other smooth muscles, the ileum and the trachea, are reported. Although not directly tested on the uterus, the smooth muscle relaxing effect could explain why it has been reported to be a uterine antispasmodic.

Anti-inflammatory Activity

Recent studies have demonstrated that this species has antioxidant, hypolipidemic, antispasmodic, analgesic, estrogenic, cytotoxic, antibacterial, antifungal, hypotensive, and broncholytic properties. The majority of these activities are related to the existence of several groups of secondary metabolites, including flavonoids, sesquiterpene lactones, coumarins, acetylenes, phenolic acids, organic acids, and mono- and sesqui-terpenes. Research published in Frontiers in Chemistry specifically identified sesquiterpene lactones from A. vulgaris as potential inhibitors of nitric oxide (NO) in LPS-induced macrophage cells, providing a mechanistic basis for anti-inflammatory activity.

Antimicrobial Activity

The essential oil of Artemisia vulgaris possesses antimicrobial activities. The essential oils of A. vulgaris, when compared with standard voriconazole, showed 50.3% and 43.02% equivalent efficacy of the antifungal activity against S. oryzae and F. oxysporum, respectively. The essential oils from A. vulgaris also showed bactericidal and fungicidal properties against Staphylococcus aureus and Candida albicans, respectively. These findings are currently limited to in vitro (laboratory) studies.

Estrogenic Activity

The presence of flavonoids eriodictyol and apigenin in A. vulgaris, with their weak estrogenic activity, may account for its folkloric use to treat menstrual disorders, as an emmenagogue and uterine relaxant. This mechanism remains characterized at the preclinical level, and no controlled human trials have verified estrogenic effects at doses encountered with typical preparations.

5. Scientific Evidence by Area of Use

5.1 Moxibustion for Breech Presentation in Pregnancy

This is the area where the strongest and most rigorous clinical evidence for an A. vulgaris-based intervention exists. The practice involves burning dried mugwort (moxa) near acupoint BL67 (Zhiyin, located on the lateral aspect of the little toe) to encourage cephalic version in pregnancies with a breech-presenting fetus.

Cochrane Systematic Review (2023): The 2023 updated Cochrane review found that when moxibustion plus usual care was compared with sham moxibustion plus usual care, moxibustion probably reduces the chance of non-cephalic presentation at birth (1 trial, 272 women; RR 0.74, 95% CI 0.58 to 0.95; moderate-certainty evidence). Moderate-certainty evidence from one study shows that moxibustion plus usual care probably reduces the use of oxytocin before or during labour. However, moxibustion plus usual care probably results in little to no difference in the rate of caesarean section, and the effects on the chance of premature rupture of membranes and cord blood pH less than 7.1 are uncertain. Adverse events were inadequately reported in most trials.

Meta-analysis (2021): Acupuncture-type interventions (such as moxibustion and acupuncture) at Bladder 67 (BL67, Zhiyin point) have been proposed to have positive effects on breech presentation. In a systematic review and meta-analysis including sixteen RCTs involving 2,555 participants, moxibustion significantly increased cephalic presentation at birth (RR = 1.39; 95% CI = 1.21–1.58).

Prior systematic review (2008): Ten RCTs involving 2,090 participants and seven CCTs involving 1,409 participants were included in a separate earlier analysis. Meta-analysis showed significant differences between moxibustion and no treatment (RR 1.35, 95% CI 1.20 to 1.51; 3 RCTs). Comparison between moxibustion and knee-chest position did not show significant differences (RR 1.30, 95% CI 0.95 to 1.79; 3 RCTs). Moxibustion plus other therapeutic methods showed significant beneficial effects (RR 1.36, 95% CI 1.21 to 1.54; 2 RCTs).

Evidence assessment: This body of evidence found limited but positive evidence to support the use of moxibustion for correcting breech presentation. There is some evidence to suggest that the use of moxibustion may reduce the need for oxytocin. When combined with acupuncture, moxibustion may result in fewer births by caesarean section; and when combined with postural management techniques, may reduce the number of non-cephalic presentations at birth. However, there is a need for well-designed randomised controlled trials to evaluate moxibustion for breech presentation which report on clinically relevant outcomes as well as the safety of the intervention. Overall, this area of evidence is rated as moderate certainty by the Cochrane reviewers and represents the most robustly studied clinical application of mugwort.

Important caveat: This evidence base is for smoke and heat application, not for drinking mugwort tea. Oral tea does not inherit the moxibustion evidence base.

5.2 Gynecological and Menstrual Applications

For many centuries, this species has been mainly used for treating gynecological ailments and gastrointestinal diseases. This plant possesses many pharmacological properties including anti-inflammatory, anti-hypertensive, antioxidant, anti-tumoral, immunomodulatory, hepatoprotective, anti-malarial, anti-spasmodic, and anti-septic properties. However, rigorous human clinical trial data specifically evaluating oral A. vulgaris preparations for dysmenorrhea, amenorrhea, or other menstrual conditions in controlled settings is absent from the peer-reviewed literature. The mechanistic basis—weak estrogenic flavonoids and smooth-muscle-relaxing activity—remains supported only by preclinical and in vitro evidence.

5.3 Antimicrobial Activity

Evidence for antimicrobial activity resides entirely in in vitro studies. Results reveal that A. vulgaris oil is a rich source of monoterpene and sesquiterpene compounds. Furthermore, A. vulgaris is a rich source of phenolic and flavonoid compounds and shows good antioxidant and antibacterial activity in laboratory models. Essential oils from A. vulgaris showed bactericidal and fungicidal properties against Staphylococcus aureus and Candida albicans, respectively, while anthelmintic activity against Haemonchus contortus was absent in one study. No human clinical trials have tested A. vulgaris as a direct antimicrobial agent.

5.4 Antioxidant and Hepatoprotective Activity

Authors have confirmed the beneficial properties of A. vulgaris herb extracts, including their antioxidant and hepatoprotective effects. These findings originate from preclinical (cell-based and animal) studies. No controlled human trials specifically evaluating liver-protective or antioxidant endpoints with standardized A. vulgaris preparations have been identified in the peer-reviewed literature.

5.5 Gastrointestinal Applications

This species has been used in traditional Chinese, Hindu, and European medicine to regulate the functioning of the gastrointestinal system. The bitter constituents of the plant, including sesquiterpene lactones and essential oil components, support a plausible mechanism for stimulating digestive secretions and improving appetite, analogous to other bitter herbs. However, clinical trial data in humans for these gastrointestinal indications is not available in the current peer-reviewed literature for A. vulgaris specifically.

5.6 Anti-inflammatory Activity

Artemisia species have a broad range of pharmacological activities including anti-inflammatory actions. For A. vulgaris specifically, long traditional usage and functional preclinical studies of different Artemisia species for the treatment of several diseases have encouraged their clinical evaluation to support evidence of their potential as anti-inflammatory agents. Current evidence for A. vulgaris anti-inflammatory activity remains at the in vitro and animal model level, with no published human clinical trials specifically addressing this endpoint.

5.7 Anticancer/Cytotoxic Activity

Confirmed cytotoxic effects of A. vulgaris herb extracts have been described in the literature. These findings are derived entirely from in vitro cell-line studies. No clinical trials evaluating A. vulgaris preparations for any oncological indication have been identified. Evidence in this area is very preliminary.

5.8 Neurological / Oneirogenic Claims

The dried leaves can be smoked or used to make a tea, purportedly to promote lucid dreaming. This supposed oneirogenic effect is reported to be due to the thujone contained in the plant. No controlled trials have measured dream outcomes from oral mugwort tea. GABA-A modulation provides mechanistic plausibility, but the closest human data involves thujone doses far exceeding those in a typical cup of tea. At standard steep strength, the dream claim is anecdotal. This indication lacks any clinical evidence.

6. Body Systems and Health Areas of Association

• Reproductive/Gynecological system: Historically used as emmenagogue, uterine relaxant, and to treat dysmenorrhea and amenorrhea; mechanistically supported by weak estrogenic flavonoids (preclinical data only for oral preparations).
• Musculoskeletal/Pain: Moxibustion form has moderate-certainty clinical evidence for cephalic version in breech presentation; anti-nociceptive effects described preclinically.
• Gastrointestinal system: Traditional use as bitter digestive tonic; antispasmodic activity documented in preclinical models.
• Immune/Infectious disease: In vitro antibacterial and antifungal activity documented; no human clinical evidence.
• Liver/Hepatic: Hepatoprotective activity in preclinical models; no human data.
• Cardiovascular: Hypotensive and broncholytic effects have been described in preclinical research.
• Neurological: Thujone-mediated GABA-A modulation hypothesized; claims of oneirogenic and anticonvulsant effects are anecdotal or derive from ethnomedicine without clinical support.
• Metabolic/Endocrine: A. vulgaris should be used with caution in patients with diabetes, as it can increase blood glucose levels.
• Respiratory/Allergic system: Mugwort pollens are known to trigger type 1 allergic reactions like allergic rhinitis, conjunctivitis, and asthma. Mugwort is also linked with plant-derived food allergies (pollen-food allergy syndrome), clinically manifested as oral allergy syndrome, angioedema, urticaria, or even anaphylaxis.

7. Dosage Forms and Reported Dosages

There are currently no standardized, evidence-based dosing regimens established by regulatory health bodies (such as EMA or WHO) specifically for A. vulgaris oral preparations. The following dosages are those reported or cited in available sources:

• Herbal tea (infusion): Prepared by pouring boiling water over one teaspoon (about 1.2 g) of dried herb and brewing the mixture covered for about 5 minutes.
• Moxibustion (for breech presentation): Best started between 33 and 36 weeks of pregnancy, applied 20 minutes per toe daily for 10 days. This involves external burning of moxa near acupoint BL67, not internal consumption.
• Thujone intake limits: The consumption of thujone from Artemisia must not exceed 10 mg/kg according to the European Food Safety Authority (EFSA) and 3 mg/day/person according to the European Medicines Agency (EMA).

8. Safety Considerations and Known Interactions

Pregnancy and Uterine Stimulation

Some Artemisia species are used in regulating fertility and should be avoided in pregnancy due to the possible risk of embryotoxicity at higher doses. A. vulgaris is reported as a uterine stimulant, and allergic skin reactions and abortive activity have been described in the pharmacological literature. These properties make oral use of A. vulgaris preparations contraindicated during pregnancy in traditional and ethnopharmacological references.

Thujone Neurotoxicity

The EFSA lists that the ingredients in the essential oil of A. vulgaris herb, such as α-thujone, β-thujone, camphor, and 1,8-cineole, have potentially adverse effects on human health when taken with food or dietary supplements; however, it emphasizes that most research has concerned only a more concentrated oil, and not a less concentrated extract. The EFSA classified the essential oil components of A. vulgaris, such as α-thujone, β-thujone, camphor, and 1,8-cineol, as having potentially adverse effects on human health when taken with food or dietary supplements. A documented acute thujone poisoning case has been associated with repeated ingestion of a concentrated A. vulgaris infusion.

Pollen Allergy and Cross-Reactivity

Mugwort pollen is one of the most clinically significant weed allergens in temperate zones. Mugwort (Artemisia vulgaris) is a major cause of weed pollen allergy in Europe but is also distributed across parts of Asia and North America. About 10% to 14% of patients with pollen allergy have a relevant sensitization to mugwort pollen.

The mugwort proteins, namely Art v 1, Art v 2, Art v 3, Art v 4, Art v 5, and Art v 6, have been identified as having allergenic potential. Mugwort and ragweed pollens show a high level of cross-reactivity since they are related weeds. Further, mugwort also cross-reacts with many food allergies leading to pollen-food allergy syndrome like mugwort-celery-spice, mugwort-fennel, mugwort-mustard, mugwort-peach, and mugwort-sunflower syndrome.

Pollinosis patients often display adverse reactions upon the ingestion of plant-derived foods as a result of IgE cross-reactive structures shared by pollen and food allergen sources. The symptoms of such pollen-food syndromes range from local oral allergy syndrome to severe systemic anaphylaxis. Two clinical syndromes—the celery-mugwort-spice syndrome and the mugwort-mustard-allergy syndrome—have been described in association with weed pollinosis.

Skin contact dermatitis has been reported upon exposure to different Artemisia species. Skin prick testing showed that the majority of patients with allergic rhinitis and asthma have positive reactions to A. vulgaris.

Cross-Reactivity with Asteraceae Family

Due to its membership in the Asteraceae family, individuals with known hypersensitivity to other Asteraceae plants—such as chamomile, ragweed, chrysanthemum, and echinacea—should exercise caution when considering any preparation containing A. vulgaris. In patients with respiratory allergy, cross-reactivity between aeroallergens and foods may induce food allergy, with symptoms ranging from oral allergy syndrome to severe anaphylaxis.

Metabolic Interactions

Therefore, A. vulgaris should be used with caution in patients with diabetes as it can increase blood glucose levels. The species is also not recommended for the prevention of malaria, and in vitro studies have not shown protozoicidal activity. It was reported that patients who used A. vulgaris as a prophylactic agent when traveling to eastern Africa were not prevented from developing malaria.

EFSA Safety Assessment

A mugwort tincture product is specified to contain a minimum of 0.01% hydroxycinnamic acid derivatives (expressed as chlorogenic acid). However, since 74% of the dry matter fraction of the additive remains uncharacterized, the EFSA Panel cannot conclude on the safety of the additive at the proposed use levels. This underscores the general point that commercial preparations of mugwort remain incompletely characterized from a safety standpoint.

References

• Ekiert H, et al. "Significance of Artemisia Vulgaris L. (Common Mugwort) in the History of Medicine and Its Possible Contemporary Applications Substantiated by Phytochemical and Pharmacological Studies." PMC / Molecules, 2020.
• Abiri R, et al. "Towards a better understanding of Artemisia vulgaris: Botany, phytochemistry, pharmacological and biotechnological potential." PubMed / Industrial Crops and Products, 2018.
• ScienceDirect Topics: Artemisia vulgaris — Overview (Pharmacology, Toxicology and Pharmaceutical Science).
• Ciocarlan A, et al. "Unveiling the Phytochemical Profile and Biological Potential of Five Artemisia Species." PMC / Plants, 2022.
• Singh A, et al. "Phytochemical Composition and Antimicrobial Activity of Essential Oil from the Leaves of Artemisia vulgaris L." PMC / Antibiotics, 2023.
• Shrestha S, et al. "Chemical composition, antioxidant and antibacterial activities of essential oil and methanol extract of Artemisia vulgaris and Gaultheria fragrantissima collected from Nepal." PubMed / Journal of Ethnopharmacology, 2017.
• Grandi M, et al. "Chemical Profile and Biological Activities of Essential Oil from Artemisia vulgaris L. Cultivated in Brazil." PMC / Molecules, 2019.
• Zou G, et al. "Sesquiterpene lactones from Artemisia vulgaris L. as potential NO inhibitors in LPS-induced RAW264.7 macrophage cells." Frontiers in Chemistry, 2022.
• Coyle ME, Smith CA, Peat B. "Cephalic version by moxibustion for breech presentation." Cochrane Database of Systematic Reviews, 2023.
• Liao JA, et al. "Correction of Breech Presentation with Moxibustion and Acupuncture: A Systematic Review and Meta-Analysis." PMC / Healthcare, 2021.
• Huang DM, et al. "Moxibustion and other acupuncture point stimulation methods to treat breech presentation: a systematic review of clinical trials." PMC / Chinese Medicine, 2009.
• Bora KS, et al. "Artemisia spp.: An Update on Its Chemical Composition, Pharmacological and Toxicological Profiles." PMC / Frontiers in Pharmacology, 2022.
• Ekiert H, et al. "Artemisia Species with High Biological Values as a Potential Source of Medicinal and Cosmetic Raw Materials." PMC / Molecules, 2022.
• Pastorello EA, et al. "Hypersensitivity to mugwort (Artemisia vulgaris) in patients with peach allergy is due to a common lipid transfer protein allergen." Journal of Allergy and Clinical Immunology, 2002.
• Popescu FD. "Cross-reactivity between aeroallergens and food allergens." PMC / World Journal of Methodology, 2015.
• Egger M, et al. "Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view." Allergy (Wiley), 2006.
• EFSA FEEDAP Panel. "Safety and efficacy of a tincture derived from Artemisia vulgaris L. (Mugwort tincture) when used as a sensory additive in feed for all animal species." EFSA Journal / PMC, 2020.
• Bakkali F, et al. "The Artemisia L. Genus: A Review of Bioactive Essential Oils." PMC / Medicines, 2018.
• Wikipedia: Artemisia vulgaris.